Citation 85863

MATSUURA,H:. (2001). SAPONINS IN GARLIC AS MODIFIERS OF THE RISK OF CARDIOVASCULAR DISEASE.. 131(3S)

Citation Details

Title	SAPONINS IN GARLIC AS MODIFIERS OF THE RISK OF CARDIOVASCULAR DISEASE.
Authors	MATSUURA,H:
Year	2001
Volume	131
Issue	3S

Summary

Year: 2001

Journal: Unknown

Organisms and Their Experiments (3)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GLYCYRRHETINIC ACID	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CHLOROGENIN,BETA:	INACTIVE
2	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B,PROTO:	INACTIVE
3	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B	ACTIVE
4	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B	ACTIVE
5	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B	ACTIVE
6	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B	ACTIVE
7	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B	WEAK ACTIVITY
8	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B	WEAK ACTIVITY
9	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	ERUBOSIDE B	WEAK ACTIVITY
10	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SATIVOSIDE B-1	WEAK ACTIVITY
11	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	SATIVOSIDE B-1 SP	ACTIVE
12	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	AGIGENIN	ACTIVE
13	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	AMPELOSIDE B-F-1	INACTIVE
14	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	AMPELOSIDE B-S-1	ACTIVE
15	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	LAXOGENIN	ACTIVE
16	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CHINENOSIDE I	WEAK ACTIVITY
17	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CHINENOSIDE I SP	ACTIVE

Allium sativum (LILIACEAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	FUROSTANE-3-BETA-6-BETA-22-26-TETRAOL,5-ALPHA: 26-O-BETA-D-GLUCOPYRANOSYL-22-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-BETA-D-GALACTOPYRANOSIDE,25(R):CHLOROGENIN,BETA: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)]-O-BETA-D-GALACTOPYRANOSIDE	None
2	HYPOCHOLESTEROLEMIC ACTIVITY	PHARMACOLOGY OF EXTRACT - IN VIVO	FUROSTANE-3-BETA-6-BETA-22-26-TETRAOL,5-ALPHA: 26-O-BETA-D-GLUCOPYRANOSYL-22-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-BETA-D-GALACTOPYRANOSIDE,25(R):	ACTIVE
3	HYPOCHOLESTEROLEMIC ACTIVITY	PHARMACOLOGY OF EXTRACT - IN VIVO	FUROSTANE-3-BETA-6-BETA-22-26-TETRAOL,5-ALPHA: 26-O-BETA-D-GLUCOPYRANOSYL-22-HYDROXY: 3-O-BETA-D-GLUCOPYRANOSYL(1-2)-O-[BETA-D-GLUCOPYRANOSYL(1-3)]-O-BETA-D-GLUCOPYRANOSYL(1-4)-O-[ALPHA-L-RHAMNOPYRANOSYL(1-2)-O-BETA-D-GALACTOPYRANOSIDE,25(R):	ACTIVE

Show SPARQL Queries (1)